On the stock market since 2021, it operates in the world of health and science. It has 106 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Buys outnumber sells, but taken together the trades don’t add up to a strong signal of confidence.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.
Clearly below the class average.
Clearly below the class average.
The price is looking for direction — no strong breakout, no collapse.
Growth: Sales growth trails the sector average.
Business Quality: Profit power and business quality trail similar companies in the sector.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
An investor who bought at the very peak is down 69% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The average analyst price target is $17.50 — 125% above today’s price.
A loss of $106.2M against $0 in annual sales.
At the current pace of spending, the cash lasts about 1.4 years. After that, the company needs to find new money.
On our five-subject report card, AURA sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: AURA is a high-risk stock — not yet profitable, and its future rides on its product catching on.
Analysts’ average target sits above today’s price, yet the valuation grade (39/100) says the stock isn’t cheap.